Therapeutic use of pleuromutilins
AssigneeNabriva Therapeutics AG
InventorsMichael Hafner, Susanne Paukner, Wolfgang Wicha, Rosemarie Riedl, Zrinka Ivezic-Schoenfeld
Life of this patent
Estimating the term…
Loading patent…
AssigneeNabriva Therapeutics AG
InventorsMichael Hafner, Susanne Paukner, Wolfgang Wicha, Rosemarie Riedl, Zrinka Ivezic-Schoenfeld
Estimating the term…
A compound of formula (I) wherein n is 0 to 4; m is 0 or 1 with the proviso that the sulphur atom and R3 are in vicinal position (if m=0 then R3 is in position 2′, and if m=1 then R3 is on position 1′); R is ethyl or vinyl; R1 is hydrogen or (C1-6)alkyl, R2 is hydrogen or (C3-6)cycloalkyl, or unsubstituted (C1-6)alkyl, or (C1-6)alkyl substituted by one or more of hydroxy; preferably one or two, methoxy, halogen, (C3-6)cycloalkyl, or R1 and R2 together with the nitrogen atom to which they are attached form a 5 to 7 membered heterocyclic ring containing at least 1 nitrogen atom or 1 nitrogen and 1 additional heteroatom e. g. selected from N or O, or R1 is hydroxy and R2 is formyl; R3 is OH, OR4, a halogen atom, or R3 is bound to 2′ and represents —O—(CH2)p—O— with p is 2 or 3; R4 is unsubstituted (C1-6)alkyl or (C3-6)cycloalkyl, or a pharmaceutically acceptable salt, solvate, prodrug or metabolite thereof for the specific use in the treatment or prevention of an inflammatory disease which is not mediated by bacteria.
A method for treating or preventing an inflammatory disease which is not mediated by bacteria comprising administering to a subject in need thereof a compound of formula (I)
-33. (canceled)
Lefamulin in form as an acid addition salt with itaconic acid, optionally Lefamulin itaconate.
Dependencies are inferred from the claim text.